Kiniksa PharmaceuticalsKNSA
13F holders, Q4 2025 (December 31)1holders −1
0new positions
1sold out
$41.27avg. 13F price*
At the end of Q4 2025, 1 institutions reported holding Kiniksa Pharmaceuticals Ltd. (KNSA) in their 13F filings, down 1 from Q3 2025. 0 opened new positions and 1 sold out. The largest holder was Harbor Capital Advisors, Inc. ($889K).
- Company
- Kiniksa Pharmaceuticals Ltd.
- CUSIP
- G5269C101
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $1.2M |
All 13F filers, Q3 2025 → Q4 2025: 843 shares bought and 30,000 shares sold, net −29,157 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Harbor Capital Advisors, Inc. | 0.07% | Add +4.1% | 21,543 | $889K |
"% of holder's portfolio" is KNSA's weight in each manager's 13F, not the share of Kiniksa Pharmaceuticals Ltd. the manager owns.